CH

Chiasma

- NASDAQ:CHMA
Last Updated 2019-08-23

LinkedIn Profile

Access Chiasma historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
nasdaq:chma 719282 Jul 29th, 2019 12:00AM Chiasma 2.0K 28.00 Open Biotechnology Jul 29th, 2019 09:55AM Jul 29th, 2019 09:55AM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 28th, 2019 12:00AM Chiasma 2.0K 28.00 Open Biotechnology Jul 28th, 2019 02:36PM Jul 28th, 2019 02:36PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 27th, 2019 12:00AM Chiasma 2.0K 28.00 Open Biotechnology Jul 27th, 2019 12:34PM Jul 27th, 2019 12:34PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 26th, 2019 12:00AM Chiasma 2.0K 28.00 Open Biotechnology Jul 26th, 2019 01:30PM Jul 26th, 2019 01:30PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 25th, 2019 12:00AM Chiasma 2.0K 28.00 Open Biotechnology Jul 25th, 2019 12:08PM Jul 25th, 2019 12:08PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 24th, 2019 12:00AM Chiasma 2.0K 28.00 Open Biotechnology Jul 24th, 2019 04:08PM Jul 24th, 2019 04:08PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 23rd, 2019 12:00AM Chiasma 1.9K 28.00 Open Biotechnology Jul 22nd, 2019 10:15PM Jul 22nd, 2019 10:15PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 22nd, 2019 12:00AM Chiasma 1.9K 28.00 Open Biotechnology Jul 21st, 2019 10:15PM Jul 21st, 2019 10:15PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 21st, 2019 12:00AM Chiasma 1.9K 28.00 Open Biotechnology Jul 21st, 2019 01:15PM Jul 21st, 2019 01:15PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 Jul 20th, 2019 12:00AM Chiasma 1.9K 28.00 Open Biotechnology Jul 20th, 2019 03:11PM Jul 20th, 2019 03:11PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.